CompletedNCT03512717Updated Mar 26, 2019

Efficacy and Safety of Potenfill for Temporary Penile Enhancement

An interventional study of Potenfill and Powerfill in Penile Enhancement, sponsored by Medy-Tox. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-26.

Sponsored by Medy-Tox · Not applicable, Interventional, and Treatment

From the registry’s dates

Registered 5 months after the study started (first participant enrolled Nov 2017, registered Apr 2018).

Phase: Not applicable
Study type: Interventional
Enrollment: 76
Allocation: Randomized
Ages: 19 Years to 65 Years
Sex: Male

Study summary

The purpose of this study is to evlauate the efficacy and safety of poteinfill, compared to the powerfill.

Conditions studied

Penile Enhancement

In context

Lead sponsor

Medy-Tox is the lead sponsor of 48 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 19 Years to 65 Years
Sexes eligible: Male
Accepts healthy volunteers: Yes

Inclusion criteria

Male subjects aged above 19 and below 65. (20≤male≥65)
be rating himself, when screening, as "Small or Very Small" on Self-Questioned Questionnaire ( SQQ) including the question: " How do you rate your penile size? // Very small, Small, Normal, Big, Very Big?"
Subjects will sign an informed consent form

Exclusion criteria

Exclusion Criteria:

Prior treatment for penile enhancement (e.g. fat, dermal graft).
Subjects who have penile malformation (e.g. Peyronie's disease), which can make impossible to perform the intervention
Allergic to hyalluronic acid.
Inflammatory or/and infectious disease on penis that can affect on this study

Study design

Phase: Not applicable
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Double (Participant, Outcomes assessor)
Enrollment: 76 participants (actual)

Study arms

Experimental
Potenfill
Device: Potenfill
Active comparator
Powerfill
Device: Powerfill

Interventions

DevicePotenfill
Maximum: 22ml
DevicePowerfill
Maximum: 22ml

What researchers measure

Primary outcomes

the Penile Circumference difference at 24 weeks from baseline
Penile Circumference: The average of Distal-, Mid-, and Proximal-penis measurements when relaxed by tape measurement
Time frame: 24 weeks

Study locations

1 site

Gangdong Sacred Heart Hospital, Hallym Univ
Seoul, Korea, Republic of

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT03512717
Lead sponsor: Medy-Tox
Responsible party: Sponsor
First posted: May 1, 2018
Start date: Nov 16, 2017
Primary completion: Jul 31, 2018
Completion: Jul 31, 2018
Last update: Mar 26, 2019

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Medy-Tox

Start the discussion